GlassScriptPhysician profile
Rushang D Patel
NPI 1891956892
$398,769.28
in general payments reported to CMS, 2019-2025
34 companies · $187K in 2025
The $187K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $99.00 · 2021: $1,719 · 2022: $5,255 · 2023: $65K · 2024: $100K · 2025: $187K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Consulting Fee: $92K · Travel and Lodging: $28K · Food and Beverage: $8,070 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $223,275.63 |
| Consulting Fee | $91,745.00 |
| Travel and Lodging | $27,813.34 |
| Food and Beverage | $8,070.38 |
| Education | $287.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $94,982.78 | 2023-2025 | Rybrevant, Carvykti, Tecvayli |
| Kite Pharma, INC. | $72,600.19 | 2019-2025 | Yescarta |
| Seagen INC. | $57,504.46 | 2019-2023 | Adcetris |
| Pfizer INC. | $48,274.37 | 2022-2025 | |
| Genmab U.S., INC. | $46,463.52 | 2023-2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $32,342.12 | 2022-2025 | Clonoseq |
| Celgene Corporation | $20,893.41 | 2019-2025 | Breyanzi, Pomalyst, Abecma |
| Abbvie INC. | $17,593.27 | 2019-2025 | |
| Gilead Sciences, INC. | $2,800.00 | 2022 | |
| Genzyme Corporation | $1,951.78 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $1,511.35 | 2019-2024 | |
| Glaxosmithkline, LLC. | $241.22 | 2021-2022 | |
| Legend Biotech USA INC. | $233.70 | 2024-2025 | Carvykti |
| Astellas Pharma US INC | $231.26 | 2020-2024 | |
| Daiichi Sankyo INC. | $218.20 | 2023-2025 | Vanflyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $185.20 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $164.00 | 2023-2025 | Tecvayli |
| Incyte Corporation | $101.39 | 2023-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $81.82 | 2022-2023 | Livtencity |
| Jazz Pharmaceuticals INC. | $67.14 | 2019 | |
| Ambu INC. | $55.55 | 2024 | |
| Sanofi-Aventis U.S. LLC | $51.08 | 2022 | |
| Stemline Therapeutics INC. | $44.96 | 2019-2025 | Elzonris |
| Beigene USA, INC. | $35.43 | 2023 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $34.46 | 2023 | Tavalisse, Rezlidhia |
| Astrazeneca Pharmaceuticals LP | $30.50 | 2019 | |
| Amgen INC. | $25.77 | 2019 | |
| Adc Therapeutics America, INC. | $22.78 | 2025 | |
| Kadmon Pharmaceuticals LLC | $14.81 | 2021 | |
| Genentech USA, INC. | $12.76 | 2023 | Lunsumio, Columvi |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rushang Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.